Vizimpro (dacomitinib) — Medica
Non-small cell lung cancer (NSCLC)
Initial criteria
- Patient is age ≥ 18 years
- Patient has advanced or metastatic disease
- Patient has sensitizing EGFR mutation-positive non-small cell lung cancer as detected by an approved test (examples: exon 19 deletions, exon 21 [L858R] substitution mutations, L861Q, G719X, S768I)
Approval duration
1 year